NCT07324161 · RECRUITING
Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease
This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive device that uses magnetic pulses to stimulate the brain — can improve symptoms in people who already have mild to moderate Alzheimer's disease. Half of participants receive real rTMS; the other half receive a sham (inactive) version as a comparison. It is a Phase NA trial, meaning it is focused on directly measuring effectiveness and safety rather than early-stage dose-finding.
You may qualify if
- Meets the 2018 NIA-AA diagnostic criteria for Alzheimer's disease (AD)
- Meets DSM-5 diagnostic criteria
- Mild to moderate disease severity (CDR Global Score 1 to 2)
- Evidence of AD pathology: positive amyloid PET OR positive cerebrospinal fluid (CSF) AD biomarkers OR positive plasma AD biomarkers
You're excluded if
- Contraindications to rTMS treatment
- Severe complications or immune diseases
- Unable to cooperate with study procedures
- History of epilepsy
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-01-14